Toronto Dominion Bank reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 283,143 shares of the medical research company’s stock after selling 1,544 shares during the quarter. Toronto Dominion Bank owned approximately 0.07% of Thermo Fisher Scientific worth $83,132,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of TMO. Ipswich Investment Management Co. Inc. grew its stake in shares of Thermo Fisher Scientific by 0.5% in the second quarter. Ipswich Investment Management Co. Inc. now owns 7,773 shares of the medical research company’s stock worth $2,283,000 after purchasing an additional 35 shares in the last quarter. Intrust Bank NA lifted its holdings in Thermo Fisher Scientific by 1.0% in the first quarter. Intrust Bank NA now owns 4,213 shares of the medical research company’s stock worth $1,153,000 after purchasing an additional 42 shares during the period. V Wealth Advisors LLC grew its position in Thermo Fisher Scientific by 0.9% in the 2nd quarter. V Wealth Advisors LLC now owns 5,035 shares of the medical research company’s stock valued at $1,479,000 after buying an additional 46 shares in the last quarter. MBM Wealth Consultants LLC grew its position in Thermo Fisher Scientific by 3.4% in the 2nd quarter. MBM Wealth Consultants LLC now owns 1,401 shares of the medical research company’s stock valued at $415,000 after buying an additional 46 shares in the last quarter. Finally, Acima Private Wealth LLC increased its stake in Thermo Fisher Scientific by 5.4% during the 1st quarter. Acima Private Wealth LLC now owns 936 shares of the medical research company’s stock valued at $256,000 after buying an additional 48 shares during the period. Institutional investors own 88.19% of the company’s stock.
A number of research firms have commented on TMO. Needham & Company LLC boosted their price target on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. BTIG Research increased their price objective on shares of Thermo Fisher Scientific to $320.00 and gave the company a “buy” rating in a report on Thursday, May 23rd. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 price objective on the stock in a research note on Wednesday, June 12th. UBS Group boosted their target price on Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a report on Thursday, May 23rd. Finally, Wolfe Research initiated coverage on Thermo Fisher Scientific in a research report on Thursday, May 30th. They issued an “outperform” rating for the company. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $303.17.
Shares of NYSE TMO traded up $4.93 during midday trading on Wednesday, reaching $294.43. The company’s stock had a trading volume of 46,173 shares, compared to its average volume of 1,376,425. Thermo Fisher Scientific Inc. has a one year low of $208.34 and a one year high of $305.45. The company has a market cap of $116.95 billion, a price-to-earnings ratio of 26.48, a price-to-earnings-growth ratio of 1.91 and a beta of 1.12. The company has a 50 day moving average price of $280.88 and a 200 day moving average price of $276.16. The company has a current ratio of 1.49, a quick ratio of 1.07 and a debt-to-equity ratio of 0.58.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.01 by $0.03. The firm had revenue of $6.32 billion during the quarter, compared to analysts’ expectations of $6.31 billion. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The firm’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period last year, the firm posted $2.75 earnings per share. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.24 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, September 17th will be paid a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 0.26%. The ex-dividend date is Monday, September 16th. Thermo Fisher Scientific’s dividend payout ratio is presently 6.83%.
In related news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $284.83, for a total value of $14,241,500.00. Following the completion of the transaction, the chief executive officer now owns 342,193 shares in the company, valued at approximately $97,466,832.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jim P. Manzi sold 1,833 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $272.93, for a total value of $500,280.69. Following the completion of the transaction, the director now directly owns 28,592 shares in the company, valued at approximately $7,803,614.56. The disclosure for this sale can be found here. Insiders own 0.45% of the company’s stock.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Story: How liquidity affects the bid-ask spread
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.